{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:08:40Z","timestamp":1780474120201,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gilteritinib is an established\n                      <jats:italic>FLT3<\/jats:italic>\n                      inhibitor used to treat patients with relapsed or refractory (R\/R) acute myeloid leukemia (AML) harboring\n                      <jats:italic>FLT3<\/jats:italic>\n                      mutations. Prior studies have predominantly evaluated gilteritinib as a posttransplant maintenance therapy in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) in complete remission. Nonetheless, evidence remains limited for patients who receive gilteritinib as salvage therapy in a relapsed or refractory setting, proceed to allo-HSCT, and subsequently continue gilteritinib maintenance. This real-world study aimed to address this knowledge gap in an Asian cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method and Result<\/jats:title>\n                    <jats:p>\n                      Patients with\n                      <jats:italic>FLT3<\/jats:italic>\n                      -mutated R\/R AML received gilteritinib before transplantation, and those achieving engraftment without grade\u2009\u2265\u20092 acute graft-versus-host disease were offered posttransplant maintenance between days 30 and 90. The cohort (median age, 48\u00a0years; 92.0%\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD) achieved a complete response (CR) rate of 76.2%. At a median follow-up of 46.2\u00a0months, gilteritinib maintenance therapy was associated with longer relapse-free and overall survival and a significantly lower 1-year cumulative incidence of relapse. Exploratory measurable residual disease (MRD) subgroup analyses suggested a numerically greater survival difference in patients without flow cytometry-detectable MRD before or after transplantation; however, the findings are limited by the small sample size and lack of\n                      <jats:italic>FLT3<\/jats:italic>\n                      -targeted next-generation sequencing-based MRD assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Gilteritinib was generally well-tolerated, with no observed increase in cytomegalovirus (CMV)-related or graft-versus-host complications. This study provides real-world evidence in a clinically relevant scenario and supports the use of gilteritinib maintenance in patients with\n                      <jats:italic>FLT3<\/jats:italic>\n                      -mutated AML who undergo transplantation during R\/R disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-026-00144-3","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:31:05Z","timestamp":1780453865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed\/refractory AML patients harboring FLT3 mutations"],"prefix":"10.1007","volume":"61","author":[{"given":"Yun-Tzu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ming","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yeh","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hau","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Lung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chieh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-En","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Kai","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"12","key":"144_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"144_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/0888-7543(91)90270-O","volume":"9","author":"O Rosnet","year":"1991","unstructured":"Rosnet O, Matte\u00ef MG, Marchetto S, Birnbaum D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics. 1991;9(2):380\u20135.","journal-title":"Genomics"},{"issue":"9","key":"144_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc1169","volume":"3","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650\u201365.","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"144_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"144_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ajh.26892","volume":"98","author":"MY Lo","year":"2023","unstructured":"Lo MY, Tsai XC, Lin CC, Tien FM, Kuo YY, Lee WH, et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023;98(5):760\u20139.","journal-title":"Am J Hematol"},{"issue":"8","key":"144_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/sj.leu.2403838","volume":"19","author":"M Yanada","year":"2005","unstructured":"Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19(8):1345\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"144_CR7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","volume":"34","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O\u2019Brien S, Koller C, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752\u20136.","journal-title":"Leuk Res"},{"issue":"5","key":"144_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"10388","key":"144_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383.","journal-title":"Lancet"},{"issue":"18","key":"144_CR10","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"7","key":"144_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"issue":"11","key":"144_CR12","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41375-024-02382-9","volume":"38","author":"J Wang","year":"2024","unstructured":"Wang J, Jiang B, Li J, Liu L, Du X, Jiang H, et al. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 2024;38(11):2410\u20138.","journal-title":"Leukemia"},{"issue":"15","key":"144_CR13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766\u201375.","journal-title":"J Clin Oncol"},{"issue":"26","key":"144_CR14","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, R\u00f6llig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993\u20133002.","journal-title":"J Clin Oncol"},{"key":"144_CR15","doi-asserted-by":"crossref","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Outcomes in patients with FLT3-mutated relapsed\/ refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transpl Cell Ther. 2023;29(4):265:e1-e10.","DOI":"10.1016\/j.jtct.2022.12.006"},{"issue":"6","key":"144_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105(6):1507\u201316.","journal-title":"Haematologica"},{"issue":"7","key":"144_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","volume":"30","author":"S Brunet","year":"2012","unstructured":"Brunet S, Labopin M, Esteve J, Cornelissen J, Soci\u00e9 G, Iori AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735\u201341.","journal-title":"J Clin Oncol"},{"issue":"5","key":"144_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/ejh.13692","volume":"107","author":"JD Griffin","year":"2021","unstructured":"Griffin JD, Song Y, Yang H, Freimark J, Shah MV. Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes. Eur J Haematol. 2021;107(5):553\u201365.","journal-title":"Eur J Haematol"},{"issue":"3","key":"144_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.14260","volume":"175","author":"AM Brunner","year":"2016","unstructured":"Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175(3):496\u2013504.","journal-title":"Br J Haematol"},{"issue":"10","key":"144_CR20","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1080\/10428194.2021.1913145","volume":"62","author":"S Shimony","year":"2021","unstructured":"Shimony S, Yeshurun M, Wolach O, Ram R, Rozovski U, Shargian L, et al. Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients \u2013 a multicenter retrospective observational study. Leuk Lymphoma. 2021;62(10):2475\u201381.","journal-title":"Leuk Lymphoma"},{"key":"144_CR21","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for Acute Myeloid Leukemia with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024:Jco2302474."},{"issue":"3","key":"144_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354\u201365.","journal-title":"Blood"},{"issue":"12","key":"144_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"1","key":"144_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-022-00774-7","volume":"13","author":"XC Tsai","year":"2023","unstructured":"Tsai XC, Sun KJ, Lo MY, Tien FM, Kuo YY, Tseng MH, et al. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer J. 2023;13(1):4.","journal-title":"Blood Cancer J"},{"issue":"12","key":"144_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41408-017-0022-y","volume":"7","author":"CH Tsai","year":"2017","unstructured":"Tsai CH, Hou HA, Tang JL, Kuo YY, Chiu YC, Lin CC, et al. Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer J. 2017;7(12):663.","journal-title":"Blood Cancer J"},{"issue":"10","key":"144_CR26","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","volume":"5","author":"CH Tsai","year":"2021","unstructured":"Tsai CH, Tang JL, Tien FM, Kuo YY, Wu DC, Lin CC, et al. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv. 2021;5(10):2456\u201366.","journal-title":"Blood Adv"},{"key":"144_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ebiom.2018.10.042","volume":"37","author":"BS Ko","year":"2018","unstructured":"Ko BS, Wang YF, Li JL, Li CC, Weng PF, Hsu SC, et al. Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine. 2018;37:91\u2013100.","journal-title":"EBioMedicine"},{"issue":"3","key":"144_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciae321","volume":"79","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, et al. Consensus definitions of Cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79(3):787\u201394.","journal-title":"Clin Infect Dis"},{"key":"144_CR29","doi-asserted-by":"crossref","unstructured":"Bornh\u00e4user M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C. Improved outcome after stem-cell transplantation in FLT3\/ITD-positive AML. Blood. 2007;109(5):2264\u20135;author reply 5.","DOI":"10.1182\/blood-2006-09-047225"},{"issue":"1","key":"144_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41409-021-01454-z","volume":"57","author":"FM Tien","year":"2022","unstructured":"Tien FM, Tsai CH, Huang SC, Liu JH, Chen CY, Kuo YY, et al. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. Bone Marrow Transplant. 2022;57(1):95\u2013105.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"144_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","volume":"12","author":"AE Perl","year":"2022","unstructured":"Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, et al. Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022;12(5):84.","journal-title":"Blood Cancer J"},{"issue":"19","key":"144_CR32","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood.2024025154","volume":"145","author":"MJ Levis","year":"2025","unstructured":"Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025;145(19):2138\u201348.","journal-title":"Blood"},{"issue":"26","key":"144_CR33","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"6","key":"144_CR34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/ijlh.14133","volume":"45","author":"M Chen","year":"2023","unstructured":"Chen M, Zeng Z, Li X, Qin W, Cai X, Chen S, et al. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients. Int J Lab Hematol. 2023;45(6):899\u2013907.","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"144_CR35","doi-asserted-by":"publisher","first-page":"e960","DOI":"10.1016\/j.clml.2021.07.011","volume":"21","author":"H Elrhman","year":"2021","unstructured":"Elrhman H, El-Meligui YM, Elalawi SM. Prognostic impact of concurrent DNMT3A, FLT3 and NPM1 gene mutations in acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 2021;21(12):e960\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"144_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","volume":"57","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2022;57(5):775\u201380.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"144_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, Baumgartner F, Braun L, O\u2019Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282\u201391.","journal-title":"Nat Med"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00144-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00144-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00144-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:50:19Z","timestamp":1780473019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00144-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["144"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00144-3","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the NTUH Research Ethics Committee. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki (approval numbers 201406099RIND and 201810058RIND).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Research funding and honorarium from Astellas: Xavier Cheng-Hong Tsai and Hsin-An Hou.No conflict of interest: Yun-Tzu Lin, Feng-Ming Tien, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Jia-Hau Liu, Bor-Sheng Ko, Chieh-Lung Cheng, Sheng-Chieh Chou, Ming-En Lin, Chien-Chin Lin, Ming-Kai Chuang, Ming Yao, Wen-Chien Chou, Hwei-Fang Tien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}